Alzamend Neuro

Alzamend Neuro is currently working to transition two therapies targeting Alzheimer's disease (AD) and psychiatric disorders from the research and preclinical stages to clinical stages, and toward full commercialization. Our lead candidate drug, AL001, is a patented ionic cocrystal technology that delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s disease and other neurodegenerative and psychiatric disorders. Our second candidate drug, AL002, is a patented approach using mutated peptide-sensitized cells as a cellular therapeutic vaccine, aiming to restore the patient's immune system to combat Alzheimer’s disease.